Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PureTech Health ( (GB:PRTC) ) has shared an update.
PureTech Health has appointed UBS as its UK Corporate Broker, a strategic move likely to enhance its financial operations and market positioning in the UK. This partnership could potentially strengthen PureTech’s industry standing and provide added value to stakeholders by facilitating better market engagement and financial support.
More about PureTech Health
PureTech Health is a clinical-stage biotherapeutics company focused on developing new classes of medicine to treat devastating diseases. With a robust pipeline created through an experienced R&D team and network of industry experts, PureTech has developed 29 therapeutics, three of which have FDA approval. The company’s programs are in various stages of clinical development, driven by its internal team and Founded Entities.
YTD Price Performance: 0.67%
Average Trading Volume: 711,166
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £362M
For an in-depth examination of PRTC stock, go to TipRanks’ Stock Analysis page.